Results 201 to 210 of about 336,346 (356)

Surviving a crisis: A multilevel model of leadership styles, employees' psychological capital and organizational resilience. [PDF]

PLoS One
Njaramba F, Olukuru J.
europepmc   +1 more source

BMP antagonist CHRDL2 enhances the cancer stem‐cell phenotype and increases chemotherapy resistance in colorectal cancer

Molecular Oncology, EarlyView.
Overexpression of CHRDL2 in colon cancer cells makes them more stem‐like and resistant to chemo‐ and radiotherapy. CHRDL2‐high cells have upregulation of the WNT pathway, genes involved in the DNA damage response (DDR) pathway and epithelial‐to‐mesenchymal transition (EMT). This leads to quicker repair of damaged DNA and more cell migration.
Eloise Clarkson, Annabelle Lewis
wiley   +1 more source

Risk assessment and management of chemical hazards for pregnant workers: a qualitative review of guidance from EU member states. [PDF]

J Occup Med Toxicol
Claessens T, Hougaard KS, Ronsmans S.
europepmc   +1 more source

Automated digital system for measuring the complex sensitivity and directivity of hydrophone arrays [PDF]

, 1982
L. D. Luker, Joseph F. Zalesak, C. K. Brown, Richard E. Scott   +3 more
openalex   +1 more source

Simultaneous inhibition of TRIM24 and TRIM28 sensitises prostate cancer cells to antiandrogen therapy, decreasing VEGF signalling and angiogenesis

Molecular Oncology, EarlyView.
TRIM24 and TRIM28 are androgen receptor (AR) coregulators which exhibit increased expression with cancer progression. Both TRIM24 and TRIM28 combine to influence the response of castrate‐resistant prostate cancer (CRPC) cells to AR inhibitors by mediating AR signalling, regulation of MYC and upregulating VEGF to promote angiogenesis. Castrate‐resistant
Damien A. Leach, Nilesh Chatterjee, Kellie Spahr, Gilberto Serrano de Almeida, Anabel Varela‐Carver, Taimur T. Shah, Mathias Winkler, Hashim U. Ahmed, Charlotte L. Bevan   +8 more
wiley   +1 more source

Three Decades of Change in Potentially Toxic Elements in Brown Algae in the Northeast Atlantic Ocean. [PDF]

Environ Sci Technol
Pacín C, Fernández JÁ, Conde-Amboage M, Lazzari M, García-Seoane R, G Viana I, Varela Z, Real C, Villares R, Aboal JR.   +9 more
europepmc   +1 more source

Tumor clusters with divergent inflammation and human retroelement expression determine the clinical outcome of patients with serous ovarian cancer

Molecular Oncology, EarlyView.
Analysis of treatment‐naïve high‐grade serous ovarian carcinoma (HGSOC) and control tissues for ERVs, LINE‐1 (L1), inflammation, and immune checkpoints identified five clusters with diverse patient recurrence‐free survivals. An inflammation score was calculated and correlated with retroelement expression, where one novel cluster (Triple‐I) with high ...
Laura Glossner, Markus Eckstein, Christoph Mark, Matthias W. Beckmann, Arndt Hartmann, Pamela L. Strissel, Reiner Strick   +6 more
wiley   +1 more source

Towards a Unified European View of Clinical Evidence: What 'Health Technology Assessment Organizations' Can Learn from Regulatory Experience. [PDF]

J Mark Access Health Policy
Broich K, Löbker W.
europepmc   +1 more source

Bantawa Rai s-, t-, and z-final verb roots: transitives, intransitives, causatives, and directives [PDF]

, 1992
R. K. Sprigg
openalex   +1 more source

Evaluation and modification of tumor cell isolation techniques from malignant effusions for rapid drug sensitivity testing

Molecular Oncology, EarlyView.
Non‐small cell lung cancer targeted treatment is limited to a few known genetic alterations, with few alternatives in advanced treatment lines. To direct treatment decisions by drug sensitivity testing (DST), this study compared several methods for tumor cell isolation from malignant effusions, pointing to repeated CD45+ cell depletion for effective ...
Navit Mooshayef, Hana Barhom, Sumit Chatterji, Netta Hecht, Oran Warhaftig, Iris Kamer, Oranit Zadok, Jair Bar, Limor Broday, Amir Onn, Michael Peled   +10 more
wiley   +1 more source